A couple of pharma stories broke after the bell last night that could impact trade today.
Immucor (BLUD) said late yesterday its first fiscal quarter earnings were flat, at $21.4 million, or $0.30 per share, compared to $21.3 million, or $0.30 per share, in the same quarter last year.
Revenue ticked slightly higher, to $83.6 million this quarter from $83.1 million last year.
Earnings per share were in-line with estimates, but revenue fell below expectations.
Immucor's fiscal 2011 forecast of $1.08 to $1.18 per share in earnings is well below expectations as well.
Also late yesterday, InterMune (NASDAQ:ITMN) said it sold worldwide development and commercialization rights for the experimental hepatitis C drug danoprevir to Roche for $175 million in cash.
The agreement ends the collaboration agreement between InterMune and Roche on the drug that began in 2006.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.